Evidence map›Paper›PMID 40756816›Full record

ReviewFrontiers in artificial intelligence2025

Artificial intelligence and machine learning in the development of vaccines and immunotherapeutics-yesterday, today, and tomorrow.

Elhoucine Elfatimi, Yassir Lekbach, Swayam Prakash, Lbachir BenMohamed

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elhoucine ElfatimiLaboratory of Cellular and Molecular Immunology, College of Medicine, The Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Yassir LekbachLaboratory of Cellular and Molecular Immunology, College of Medicine, The Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Swayam PrakashLaboratory of Cellular and Molecular Immunology, College of Medicine, The Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.
Lbachir BenMohamedLaboratory of Cellular and Molecular Immunology, College of Medicine, The Gavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of vaccines and immunotherapies against infectious diseases and cancers has been one of the significant achievements of medical science in the last century. Subunit vaccines offer key advantages over whole-inactivated or attenuated-pathogen-based vaccines, as they elicit more specific B-and T-cell responses with improved safety, immunogenicity, and protective efficacy. However, developing subunit vaccines is often cost-and time-consuming. In the past, the development of vaccines and immunotherapeutics relied heavily on trial-and-error experimentation, as well as extensive and costly

Indexed as

artificial intelligence (AI)cancerimmunotherapeuticsinfectious diseasesmachine learning (ML)vaccine development

Identifiers

PMID40756816
PMCPMC12313644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.